Cardiology_Cholesterol

The Top 5 Biomarkers in Cardiovascular Disease PreventionWhich biomarker is most useful in what situation? Find out how one cardiologist makes these decisions. Do you concur?
PCSK9 Inhibitors: A 5-Question QuizThe PCSK9 inhibitor class is here to stay. Find out what you know about the enzyme and how its inhibition is revolutionizing CHD prevention.
5 Stubborn Statin Myths vs Data that Refute ThemAt AHA.17, Dr Rory Collins offered large-scale trial data to help dispel dangerous disinformation still circulating about the effects of statins.
2017 ACC/AHA Hypertension Guidelines: Case StudyClick through this short case study for an illustration of the key principles put forth in the revised ACC/AHA guidelines on hypertension diagnosis and management.
Evolocumab Impact Significant in Patients with PADLowering LDL-C levels in FOURIER trial patients with PAD had a significant impact on both MACE and MALE.
No Difference in CV Outcomes with Statin plus Add-on vs Statin AloneThe HIJ-PROPER study found intensive LDL-lowering therapy added no additional therapeutic value in patients with ACS.
AACE/ACE Lipid Guidelines Define Extreme CVD RiskThe AACE/ACE 2017 recommendations on lipid management prescribe LDL-C targets, and go far lower than any group has ventured to date.
FOURIER Clinical Outcomes Trial Results: Center Stage at ACC.17Highly anticipated, the 2-year results support the promise of PCSK9 inhibitors and also highlight important questions.
Impact of High-dose Statin on Plaque MorphologyStatins are clinically proven to improve CV outcomes--a new study offers insight into the mechanisms at work on arterial plaque.
Quiz: When you Stop the Statin, What Next?The lifesaving potential in a statin Rx should motivate us to try, try again if side effects lead to discontinuation.